Review Papers Claim by Claim

Key strengths (visual first)

• Comprehensive mechanistic primer linking ICR/DMR biology to therapeutic rationales (e.g., targeting UBE3A-ATS to unsilence paternal UBE3A; reactivating maternal SNORD116 region in PWS) Mechanistic mapping in Chao et al.
• Balanced discussion of trial-stage symptomatic drugs for PWS (oxytocin, setmelanotide, GLP‑1R agonists, AZP‑531) with reference to registered trials and published pilot/phase studies PWS symptomatic table in review

Primary critiques and blindspots

1. Evidence level conflation: the review mixes cell, iPSC, mouse, non-human primate and early human trial evidence without a clear structured evidence‑grading table; readers need explicit confidence levels per approach (preclinical vs clinical) rather than narrative emphasis alone Authors acknowledge preclinical stage
2. Timing and developmental windows under-emphasized: the review states early intervention is important but does not quantify windows for specific IDs; for AS, mouse studies show narrow neonatal windows for maximal rescue which complicates human translation (developmental alignment missing) Timing caveat in Chao et al.
3. Off-target epigenetic risk needs quantitative appraisal: epi‑drugs (DNMT/HDAC/G9a inhibitors) are promising but can have genome‑wide effects; the review cites G9a inhibitors for PWS but does not present genome‑scale off‑target data or therapeutic index estimates — a key translational omission G9a inhibitors in review
4. Delivery and durability not resolved: AAV/ASO/CRISPR delivery to CNS and peripheral tissues remains a major barrier; the review notes both AAV success stories (LCA, hemophilia) and safety concerns but lacks quantitative vector biodistribution/safety synthesis across IDs AAV discussion in Chao et al.

Concrete, evidence‑focused recommendations (practical)

• Add an explicit evidence‑level table (GRADE style) per therapeutic axis: list model system, replication status, main phenotypes rescued, adverse signals, and clinical trial IDs (where available) — this will materially increase translational utility (review provides many trial IDs but not structured GRADE) Trial listings in Chao et al.
• Quantify off‑target burdens for epi‑drugs and ASO/CRISPR: include available genome‑wide methylation/chromatin datasets (iPSC/mouse) after G9a inhibition / dCas9‑TET1 to estimate fraction of CpGs altered and candidate off‑target gene sets.
• Recommend standardized developmental‑stage mapping (mouse→human) when reporting window-dependent rescue data (e.g., translate rodent postnatal days to human gestational/neonatal stages using established neurodevelopmental scaling) to improve clinical trial design.

Quick synthesis — what the review gets right and what to be cautious about

Representative evidence excerpts (selected citations)

• ASO approaches: ASO suppression of Ube3a‑ATS reinstates paternal Ube3a in mouse brains and shows partial phenotypic rescue; small human ASO trials are ongoing (GTX‑102, RO7248824, ION582) — promising but unproven in humans ASO section in review
• Epigenetic reprogramming (PWS): G9a (EHMT2) inhibitors (UNC0642/0638) reduced H3K9me2 at PWS‑ICR and reactivated maternal SNORD116 in mice/iPSC models, improving survival/growth in PWS neonatal mice — compelling preclinical data but human safety unknown G9a inhibitor data in review
• CRISPR‑dCas9 epigenetic editors: dCas9‑TET1 used to demethylate PWS promoters and activate genes in vivo; CRISPR‑Cas9 editing of UBE3A‑ATS reactivated paternal UBE3A and improved AS mouse phenotypes — promising mechanistic proof‑of‑principle but raises off‑target/DSB concerns CRISPR section in review

Actionable next steps for researchers (concise)

1. Publish a systematic evidence table (per modality: model, endpoints rescued, effect sizes, off‑target assays) to convert narrative claims into actionable prioritization.
2. For epi‑drugs/ATFs/dCas9 approaches: require genome‑wide methylation/chromatin assays and transcriptome profiling (multi‑omics) after treatment in relevant human neurons/iPSC lines as a gate before clinical translation.
3. Design clinically realistic delivery studies (AAV/ASO biodistribution, immunogenicity, dose‑finding) in non‑human primates aligned to human neurodevelopmental timelines to set safe windows.